Evidence map›Paper›PMID 36039144›Full record

ArticleJHEP reports : innovation in hepatology2022

The burden of non-alcoholic steatohepatitis: A systematic review of health-related quality of life and patient-reported outcomes.

Zobair Younossi, Priya Aggarwal, Ichhya Shrestha, João Fernandes, Pierre Johansen, Margarida Augusto, Sunita Nair

Open access · goldAbstract read
In one paragraph

Article in JHEP reports : innovation in hepatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
57citing papers in PubMed, 3 pooled it
14.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

57 citing papers in PubMed, 3 syntheses or guidelines pooled it, 96 citations in OpenAlex.

  1. Pooled it
  2. Impact of Choice of Tariff When Calculating Clinically Meaningful EQ-5D Scores in Metabolic Dysfunction-Associated Steatohepatitis.Liver international : official journal of the International Association for the Study of the Liver · 2025
    Pooled it
  3. Pooled it
  4. Effect of Essential Phospholipids in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Randomised Phase 4 Clinical Trial.Liver international : official journal of the International Association for the Study of the Liver · 2026
    Trial
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Single Cell Analysis Reveals the Presence of Novel Intermediate Cells in Both Mice and Patients With Severe MASLD.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026
    Article
  11. Mechanistic insights into the liver-brain axis during chronic liver disease.Nature reviews. Gastroenterology & hepatology · 2026
    Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Observational
  19. Deciphering the role ofWorld journal of hepatology · 2025
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 3 countries.

Zobair YounossiCenter for Liver Diseases and Department of Medicine, Inova Fairfax Hospital, Falls Church, VA, USA.
Priya AggarwalDRG Abacus (Clarivate), Gurgaon, Haryana, India.
Ichhya ShresthaNovo Nordisk A/S, Søborg, Denmark.
João FernandesNovo Nordisk A/S, Søborg, Denmark.
Pierre JohansenNovo Nordisk Denmark A/S, Region North & West Europe, Ørestad, Denmark.
Margarida AugustoNovo Nordisk Ltd, Gatwick, UK.
Sunita NairDRG Abacus (Clarivate), Mumbai, Maharashtra, India.
Novo Nordisk (Denmark) · DKInova Health System · USNovo Nordisk (United Kingdom) · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background & Aims: Non-alcoholic steatohepatitis (NASH) is associated with increased mortality and a high clinical burden. NASH adversely impacts patients' health-related quality of life (HRQoL), but published data on the humanistic burden of disease are limited. This review aimed to summarise and critically evaluate studies reporting HRQoL or patient-reported outcomes (PROs) in populations with NASH and identify key gaps for further research. Methods: Medline, EMBASE, the Cochrane Library and PsycINFO were searched for English-language publications published from 2010 to 2021 that reported HRQoL/PRO outcomes of a population or subpopulation with NASH. Results: Twenty-five publications covering 23 unique studies were identified. Overall, the data showed a substantial impact of NASH on HRQoL, particularly in terms of physical functioning and fatigue, with deterioration of physical and mental health as NASH progresses. Prevalent symptoms, including fatigue, abdominal pain, anxiety/depression, cognition problems, and poor sleep quality, adversely impact patients' ability to work and perform activities of daily living and the quality of relationships. However, some patients fail to attribute symptoms to their disease because of a lack of patient awareness and education. NASH is associated with high rates of comorbidities such as obesity and type 2 diabetes, which contribute to reduced HRQoL. Studies were heterogeneous in terms of diagnostic methods, population, outcomes, follow-up time, and measures of HRQoL/utility. Most studies were rated 'moderate' at quality assessment, and all evaluable studies had inadequate control of confounders. Conclusions: NASH is associated with a significant HRQoL burden that begins early in the disease course and increases with disease progression. More robust studies are needed to better understand the humanistic burden of NASH, with adequate adjustment for confounders that could influence outcomes. Lay summary: Non-alcoholic steatohepatitis (NASH) has a significant impact on quality of life, with individuals experiencing worse physical and mental health compared with the general population. NASH and its symptoms, which include tiredness, stomach pain, anxiety, depression, poor focus and memory, and impaired sleep, affect individuals' relationships and ability to work and perform day-to-day tasks. However, not all patients are aware that their symptoms may be related to NASH. Patients would benefit from more education on their disease, and the importance of good social networks for patient health and well-being should be reinforced. More studies are needed to better understand the patient burden of NASH.

Indexed as

AIS, Athens Insomnia ScaleBC, biopsy-confirmedBDI-II, Beck Depression Inventory-IIBurden of diseaseCC, compensated cirrhosisCD, cognitive debriefingCE, concept elicitationCHC, chronic hepatitis CCLD, chronic liver diseaseCLDQ, Chronic Liver Disease QuestionnaireComorbiditiesCVD, cardiovascular diseaseDisease progressione1, excluded after screening title and abstracte2, excluded after screening full textELF, enhanced liver fibrosisEPHPP, Effective Public Health Practice ProjectEQ-5D-5L, EuroQol-5D-5 levelEQ-5D, EuroQol-5DF1–4, fibrosis stages 1–4FSSG, frequency scale for the symptoms of gastro-oesophageal reflux diseaseGERD, gastro-oesophageal reflux diseaseGfK, Growth from KnowledgeGGT, gamma-glutamyl transpeptidaseGI, gastrointestinalHADS, Hospital Anxiety and Depression ScaleHCC, hepatocellular carcinomaHealth-related quality of lifeHRQoL, health-related quality of lifei1, included to screen based on title and abstracti2, included to screen full texti3, total included studies after the full-text review stage for original report and 2021 search updateMCID, minimal clinically important differenceMCS, mental component summaryNAFLD, non-alcoholic fatty liver diseaseNAFL, non-alcoholic fatty liverN/A, not availableNASHNASH, non-alcoholic steatohepatitisNAS, NAFLD activity scoreNFS, non-alcoholic fatty liver disease fibrosis scoreNICE, National Institute for Health and Care ExcellenceNIT, non-invasive testNon-alcoholic steatohepatitisNR, not reportedOR, odds ratioPatient-reported outcomesPCS, physical component summaryPHAQ, Patient-Reported Outcome Measurement Information System Health Assessment QuestionnairePRISMA, Preferred Reporting Items for Systematic Reviews and Meta-AnalysesPRO, patient-reported outcomeQD, once dailyQoL, quality of lifeRCT, randomised controlled trialSF-12, 12-item Short Form Health SurveySF-36, Short Form-36SF-6D, Short Form–6 DimensionSG, standard gambleSPAN, School Physical Activity and NutritionSymptomsT2D, type 2 diabetesVAS, visual analogue scaleWPAI:SHP, Work Productivity and Activity Impairment: Specific Health ProblemWPAI, Work Productivity and Activity Impairment

Identifiers

PMID36039144
PMCPMC9418497
OpenAlexW4282914638

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.